EC Number   |
Activating Compound |
Reference |
|---|
    1.14.14.32 | cytochrome b5 |
- |
692093, 693347 |
| 1.14.14.32 | cytochrome b5 |
plays an important role in regulating the 17,20-lyase reaction catalyzed by CYP17 |
714352 |
| 1.14.14.32 | cytochrome b5 |
plays an important role in regulating the 17,20-lyase reaction catalyzed by CYP17. Rat cytochrome b5 stimulates the 17,20-lyase activity of bovine CYP17A1 by a factor of 4-5 |
714352 |
| 1.14.14.32 | cytochrome b5 |
plays an important role in regulating the 17,20-lyase reaction catalyzed by CYP17. Rat cytochrome b5 stimulates the 17,20-lyase activity of human CYP17A1 by a factor of 5. The H67A mutant of cytochrome b5 and Zn-substituted b5 are both unable to bind heme and therefore fail to stimulate the catalytic activity of CYP17 |
714352 |
| 1.14.14.32 | cytochrome b5 |
presence of cytochrome b5 markedly stimulates the 17,20-lyase reaction, with little effect on 17-hydroxylation. For the 17-hydroxylase reaction, progesterone oxidation is the most tightly coupled (about 50%) and negligibly changed upon addition of b5. For the 17,20-lyase reactions, b5 markedly increases product formation and coupling in parallel with all substrates, from 6% to 44% with the major substrate 17-hydroxypregnenolone |
737726 |
| 1.14.14.32 | more |
serine phosphorylation of P450c17 |
693347 |
| 1.14.14.32 | P450 oxidoreductase |
- |
693347 |
| 1.14.14.32 | PD98059 |
inhibitor of the MEK/ERK pathway. Treatment of cells with PD98059 (10 mM) at 24 and 48 h results in significant increases in the protein levels of CYP17. Production of androstenedione and estradiol significantly increases after treatment with PD98059 |
738346 |
